ALNY
Alnylam Pharmaceuticals, Inc.Company with tickers: ALNY
CIK
1178670
CUSIP
02043Q107
Shares Outstanding
133,512,573
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $3,713,937,000 | USD | 2025-12-31 | 10-K | 2026-02-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $1,319,775,000 | USD | 2025-12-31 | 10-K | 2026-02-12 |
| Operating Income | $501,578,000 | USD | 2025-12-31 | 10-K | 2026-02-12 |
| Net Income | $313,747,000 | USD | 2025-12-31 | 10-K | 2026-02-12 |
| EPS (Basic) | $2.39 | USD/shares | 2025-12-31 | 10-K | 2026-02-12 |
| EPS (Diluted) | $2.33 | USD/shares | 2025-12-31 | 10-K | 2026-02-12 |